This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Jazz, Hikma, class plaintiffs get preliminary settlement nod in US Xyrem antitrust case

By Clayton Vickers ( May 15, 2025, 22:46 GMT | Insight) -- Jazz Pharmaceuticals, Hikma Pharmaceuticals and a class of indirect purchaser plaintiffs got preliminary settlement approval from a California federal judge today for overlapping claims alleging the defendants engaged in a pay-for-delay scheme over entry to the market of a generic version of the narcolepsy drug Xyrem.Jazz Pharmaceuticals, Hikma Pharmaceuticals and a class of indirect purchaser plaintiffs got preliminary settlement approval from a California federal judge today for overlapping claims alleging the pharmaceutical companies engaged in a pay-for-delay scheme over entry of a generic version of the narcolepsy drug Xyrem to the market....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections